Roche's Breast Cancer Drug Cuts Risk of Death by 30% in Phase III
RHHBY's giredestrant cuts the risk of invasive disease recurrence or death by 30% in phase III, fueling momentum for a next-generation endocrine therapy.
Roche May Be Riding A Bit Too High, But Remains Interesting
Roche has rallied on improved sentiment around the late-stage pipeline, but near-term risk/reward is less compelling given elevated expectations and thin 2026 catalysts. The upcoming persevERA read-out for giredestrant is pivotal; strong data could unlock multi-billion-dollar peak sales, but disappointment may trigger downside as expectations have risen with lidERA results. The pipeline has produced mixed results in 2025; while giredestrant, Gazyva, and early-stage assets show promise, setbacks in other programs temper enthusiasm.
Roche - Despite Some Study Setbacks, Pipeline Gives Me Increasing Confidence
Roche (OTCQX:RHHBY) is upgraded to Buy, driven by strong 2025 performance, robust pipeline, and attractive valuation metrics. RHHBY faces major patent expiries, but new launches like Phesgo, Helimbra, and Vabysmo, plus a deep pipeline, can offset losses. Obesity drug portfolio is a key differentiator; success here could drive significant revenue and share price upside for RHHBY.
RHHBY Reports Positive Phase III Data on Breast Cancer Drug
Roche reports strong phase III lidERA results as giredestrant delivers meaningful iDFS gains over standard endocrine therapy.
Roche Shares Rise After Breast-Cancer Pill Shows Positive Results in Trial
The drugmaker said the results for giredestrant open the door to adding a treatment option at an early stage of the cancer, when most patients are diagnosed.
Roche oral drug shown to keep breast cancer at bay, boosting shares
Roche's ROG.S experimental oral drug giredestrant has been shown to cut the risk of recurrence of a common form of breast cancer after surgery, boosting the company's shares and underpinning its traditional credentials in oncology.
Roche Multiple Sclerosis Drug Meets Main Goals in Two Late-Stage Trials
Fenebrutinib met primary goals in two late-stage trials for the treatment of two different forms of multiple sclerosis.
Roche says MS drug candidate meets primary goal in late-stage trial
Roche said on Monday that a late-stage trial testing its multiple sclerosis drug candidate fenebrutinib against the relapsing form of the disease achieved its primary goal.
CellBxHealth jumps 10% after unveiling Roche-linked cancer testing study
Shares in CelLBxHealth PLC (AIM:CLBX, NSX:ANPCY) rose 10% to 2.3p after the company revealed encouraging early results from a study showing its cancer cell detection platform works seamlessly with Roche's leading diagnostic equipment. The Guildford-based biotech, which specialises in analysing circulating tumour cells, live cancer cells that move through the bloodstream, presented the findings at the World ADC Conference in San Diego, the main global meeting for antibody-drug conjugate (ADC) therapies.
CellBxHealth teams up with Roche in cancer testing breakthrough
CelLBxHealth PLC (AIM:CLBX, NSX:ANPCY) has unveiled early results from a study that links its cancer cell detection technology with Roche's widely used diagnostic equipment, a step that could make blood-based cancer testing easier to integrate into hospital laboratories. The Guildford-based company, which focuses on analysing circulating tumour cells, live cancer cells that break away from tumours and travel in the bloodstream, presented its findings at the World ADC Conference in San Diego, the leading global event for antibody-drug conjugates (ADCs).
RHHBY's Sales Up 7% in First 9 Months of 2025, '25 Earnings View Raised
Roche's Q3 sales climbed 6% to CHF 14.9B, powered by surging demand for Phesgo, Xolair, Hemlibra, Vabysmo, and Ocrevus.
Roche Raises Full-Year Earnings Outlook
The pharma group lifted its guidance citing strong results to date, and reported a rise in sales excluding currency movements.
